Hydroxyurea (hydroxycarbamide)

Description générale

Hydroxyurea (also known as hydroxycarbamide) is used in the management of sickle cell disease, and in treatment protocols for chronic myeloproliferative disorders.

INN	Hydroxycarbamide
Codes ATC	L01XX05
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2009 (TRS 958) pour Chronic myeloid leukaemia, not elsewhere classified Modifié en 2009 (TRS 958) pour Squamous cell carcinoma of oropharynx Modifié en 2011 (TRS 965) pour Other specified sickle cell disorders or other haemoglobinopathies Retiré en 2015 (TRS 994) pour Squamous cell carcinoma of oropharynx
Wikipédia	Hydroxyurea (hydroxycarbamide)
DrugBank	Hydroxycarbamide (Hydroxyurea)

Recommandations

Section Cytotoxic medicines

- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Indications

Chronic myeloid leukaemia, not elsewhere classified

Squamous cell carcinoma of oropharynx

Section Medicines for haemoglobinopathies

- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies